Adalimumab 20mg/0.4mL (50mg/mL) Injection

Adalimumab 20mg/0.4mL (50mg/mL) is a subcutaneous anti-TNF biologic used for inflammatory arthritis, psoriasis, inflammatory bowel disease and non-infectious uveitis, with age- and condition-specific treatment plans.
Adalimumab is injected under the skin of the thigh or abdomen. Rotate sites and avoid bruised, tender or inflamed skin. The dose depends on the condition and, in children, body weight. A vial and a prefilled syringe require different preparation and training.
Adalimumab neutralises TNF alpha, reducing inflammatory signalling and immune-mediated tissue injury.
Injection-site redness, headache and respiratory infections are common. Serious infection, tuberculosis reactivation and severe allergic reactions require prompt care.
Screen for tuberculosis and hepatitis B before treatment. Active serious infection, demyelinating disease and heart failure affect suitability. Avoid live vaccines during treatment unless the treating team has specifically planned otherwise.
Sustained suppression of inflammation can improve function, reduce flares and limit tissue damage in a responsive condition.
Do not use hot water, a microwave or direct heat, and do not shake the solution. Let it warm naturally at room temperature before preparation to reduce injection discomfort without damaging the medicine.
A vial requires a sterile syringe and accurate measurement of the volume. A prefilled syringe has its own preparation and injection steps. Use the technique you were taught for that presentation.
These may signal tuberculosis or another infection that needs prompt assessment during TNF blockade.
Some biologic combinations increase serious-infection risk. They are not routine add-on treatments.
Subcutaneous: injected into tissue beneath the skin. Uveitis: inflammation inside the eye. TNF inhibitor: a medicine that blocks tumour necrosis factor.; AR: Adalimumab 20mg/0.4mL (50mg/mL) حقن; FR: Adalimumab 20mg/0.4mL (50mg/mL) injection; PT: Adalimumab 20mg/0.4mL (50mg/mL) injeção; ES: Adalimumab 20mg/0.4mL (50mg/mL) inyección; RU: Adalimumab 20mg/0.4mL (50mg/mL) инъекция; ID: Adalimumab 20mg/0.4mL (50mg/mL) suntikan; VI: Adalimumab 20mg/0.4mL (50mg/mL) thuốc tiêm; MS: Adalimumab 20mg/0.4mL (50mg/mL) suntikan; TL: Adalimumab 20mg/0.4mL (50mg/mL) iniksyon; ZH-SG: Adalimumab 20mg/0.4mL (50mg/mL) 注射剂
International B2B Enquiry
Send a structured B2B enquiry for Adalimumab 20mg/0.4mL (50mg/mL) Injection under Immunology Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Adalimumab 20mg/0.4mL (50mg/mL) Injection